ArticleAsian Pacific journal of cancer prevention : APJCP2025
Comparative Study of ERK1/2, Bcl2, and Sorcin with Clinicopathological Characteristics of Gastric carcinoma: Tubular Adenocarcinoma Vs Signet Ring Cell Carcinoma.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveAltered expression of tissue-specific tumor markers is associated with clinicopathological factors and poor clinical outcomes in Gastric Cancer (GC). However, the markers have been scarcely explored in the context of the distinct GC subtypes, which are crucial for assessing treatment response. This study explores the nuanced differences between gastric tubular adenocarcinoma (TA) and signet ring cell carcinoma (SRCC), focusing on the correlation of ERK1/2, Bcl2, and Sorcin expression. The aim is to identify potential differences between the subtypes and assess the prognostic value of the markers in relation to clinicopathological outcomes.
methodsImmunohistochemistry evaluated the ERK1/2, Bcl2 and Sorcin expression in 78 patients (TA=37, SRCC=33; other=8) diagnosed with advanced non-metastatic GC. Descriptive statistics and correlations were assessed between the proteins and clinicopathological features. Overall survival and hazard risk (HR) were determined using Kaplan-Meier and Cox proportional hazard analyses.
resultsHigher ERK1/2 (66%) and lower Bcl2 (51%) expression was demonstrated in SRCC, whereas the opposite trend was noted in TA cases. On the contrary, Sorcin expression was high in both, however, predominant in SRCC (66%). Notably, post-NACT, the expression of these proteins was elevated. Significant difference in survival between TA (22±3.03 months) and SRCC (12±1.62 months) (p=0.007) was observed. In SRCC, higher ERK1/2, Sorcin, and low Bcl2 expressions were associated with shorter survival with HR>1 (p<0.05). Significant correlation between Sorcin and clinicopathological factors was analysed both in TA and SRCC (p<0.001) compared to ERK1/2 and Bcl2 expression. Sorcin expression was further associate with treatment response in non-responders (post-NACT) in both TA and SRCC (p<0.05).
conclusionHigh ERK1/2, Sorcin, and low Bcl2 expression prevailed in SRCC cases. These expressions were upregulated post-NACT in both subtypes. SRCC patients had shorter OS, moreover expression of ERK1/2, Sorcin, and Bcl2 correlated with poor survival outcomes and major clinicopathological factors in SRCC cases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.